Germany · Delayed Price · Currency is EUR Eledon Pharmaceuticals Statistics
Total Valuation
FRA:2TK has a market cap or net worth of EUR 105.64 million. The enterprise value is 25.71 million.
| Market Cap | 105.64M |
| Enterprise Value | 25.71M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 75.03M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +94.74% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 43.80% |
| Float | 63.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.36 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.36 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.74, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.74 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -95.49% and return on invested capital (ROIC) is -64.20%.
| Return on Equity (ROE) | -95.49% |
| Return on Assets (ROA) | -44.22% |
| Return on Invested Capital (ROIC) | -64.20% |
| Return on Capital Employed (ROCE) | -74.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.27M |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:2TK has paid 367,341 in taxes.
| Income Tax | 367,341 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -69.19% |
| 50-Day Moving Average | 2.29 |
| 200-Day Moving Average | 2.62 |
| Relative Strength Index (RSI) | 33.65 |
| Average Volume (20 Days) | 137 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.69M |
| Pretax Income | -67.64M |
| Net Income | -70.46M |
| EBITDA | n/a |
| EBIT | -73.69M |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
The company has 79.61 million in cash and 615,361 in debt, giving a net cash position of 78.99 million.
| Cash & Cash Equivalents | 79.61M |
| Total Debt | 615,361 |
| Net Cash | 78.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 77.61M |
| Book Value Per Share | 1.29 |
| Working Capital | 69.89M |
Cash Flow
| Operating Cash Flow | -57.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:2TK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -94.74% |
| Shareholder Yield | -94.74% |
| Earnings Yield | -66.70% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 5, 2020. It was a reverse split with a ratio of 0.0555555556.
| Last Split Date | Oct 5, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0555555556 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |